Evommune, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Evommune disclosed Phase 2a proof-of-concept results for EVO301 (IL-18 binding protein) in moderate-to-severe atopic dermatitis (N=70): 34% placebo-adjusted EASI improvement at week 8 (33% at week 12); 23% achieved IGA 0/1 at week 12 versus 0% placebo; no treatment-related serious or severe adverse events. Company plans Phase 2b initiation mid-2027 with subcutaneous formulation. Additionally, EVO756 (MRGPRX2 antagonist) Phase 2b migraine trial initiated July 2026 with top-line data expected 2027, and EVO646 (TLR7/8 antagonist) Phase 1 planned 1H 2027. Cash position ~$287M with runway into 2029.
Why this rating
Phase 2a POC with comparable efficacy to marketed biologics validates lead asset and de-risks Phase 2b; represents ~$95M+ of company's $302M asset base and positions EVO301 in multi-billion dollar AD market. Meaningful near-term value creation pending Phase 2b results.
Tradability signal
NO TRADE
No trade: positive news with only -2.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.42% over 4 hrs, n=73). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $10.31 | +10 min · unknown $10.14 ▼ 1.60% | +30 min · unknown $10.04 ▼ 2.57% | +1 hr · unknown $10.02 ▼ 2.86% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.